Evidence map›Paper›PMID 30384408›Full record

ArticleToxins2018

Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.

Salma El-Behaedi, Rebekah Landsman, Michael Rudloff, Emily Kolyvas, Rakan Albalawy, Xianyu Zhang, Tapan Bera, Keith Collins, Serguei Kozlov, Christine Alewine

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Frontiers in oncology · 2021
    Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Salma El-BehaediLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. salma_el-behaedi@med.unc.edu.
Rebekah LandsmanLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. rlandsman@luc.edu.
Michael RudloffLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. michael.w.rudloff@vanderbilt.edu.
Emily KolyvasLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. ekolyvas@mcw.edu.
Rakan AlbalawyLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. Rakan.Albalawy@UToledo.edu.
Xianyu ZhangLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. xianyu.zhang@nih.gov.
Tapan BeraLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. berat@mail.nih.gov.
Keith CollinsCenter for Advanced Preclinical Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD 21702, USA. collinke@mail.nih.gov.
Serguei KozlovCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, P.O. Box B, Frederick, MD 21702, USA. kozlovse@mail.nih.gov.
Christine AlewineLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. Christine.alewine@nih.gov.ORCID 0000-0003-1661-0957

Funding

Precision Therapy to Target Pancreatic Ductal AdenocarcinomaZIABC011652 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALEWINE, CHRISTINE · 2015 to 2025
$7.9M
NCI NIH HHS ZIA BC 011652
6 · The paper itself

Abstract

LMB-100 is a mesothelin-targeted recombinant immunotoxin (iTox) that carries a modified

Indexed as

OncogenesAnimalsCell Line, TumorFemaleGPI-Linked ProteinsHumansImmunoconjugatesImmunotoxinsIntercellular Signaling Peptides and ProteinsMesothelinMiceMice, Inbred C57BLMice, NudeMice, TransgenicProtein Synthesis InhibitorsSignal TransductionGPI-Linked ProteinsImmunoconjugatesImmunotoxinsIntercellular Signaling Peptides and ProteinsLMB-100MesothelinMsln protein, mouseProtein Synthesis Inhibitorsimmunotoxinmicroenvironmentpancreatic cancerubiquitinationVEGF

Identifiers

PMID30384408
PMCPMC6267581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.